Back

Real-world use of bempedoic acid for ASCVD risk reduction in a rural UK primary care practice: Analysing trends in LDL-C reduction, adherence, and ESC target attainment

28 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Lipid-lowering agents: review, meta-analysis, efficacy, and clinical outcomes Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mrs Meredith Donaldson

Marsh Medical Practice, Louth (United Kingdom of Great Britain & Northern Ireland)

6 More presentations in this session

Presentation thumbnail
GLP-1 receptor agonist decreases VLDL-induced lipid accumulation in cardiomyocyte
Mr J. Chang (Kaohsiung, TW)
Abstract Slides
Presentation thumbnail
Heterogeneous biomarker responses to CETP inhibitors: a phase 3 trials systematic review and network meta-analysis
Professor M. Banach (Lodz, PL)
Abstract Slides
Presentation thumbnail
Class effects of subcutaneous lipoprotein(a)-lowering therapies: a systematic review and meta-analysis
Doctor M. Dogan (Greenville, US)
Abstract Slides
Presentation thumbnail
Comparative LDL-C Reduction and Cardiovascular Outcomes With PCSK9-Pathway Therapies: A Systemic Review and Network Meta-Analysis
Doctor H. Ramteke (Chimur, IN)
Abstract Slides
Presentation thumbnail
Upfront combination lipid-lowering therapy in statin-naive acute coronary syndrome patients with high admission LDL-C: real-world support for the 2025 ESC dyslipidaemias guidelines
Mr A. Meseguer Hernandez (Cartagena, ES)
Abstract Slides

Access the full session

Session thumbnail
Lipid-lowering agents: review, meta-analysis, efficacy, and clinical outcomes

The Event

Event poster

ESC Congress 2026

28 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Impact of bempedoic acid alone and combined with ezetimibe on ldl-cholesterol reduction: graphical evidence and retrospective analysis of a real-world clinical cohort
24 April 2026
thumbnail
Congress Presentation
Updated treatment thresholds in the 2019 ESC/EAS dyslipidaemia guidelines substantially expand indications for statin use for primary prevention at population level: results from the Rotterdam Study
30 August 2020
thumbnail
Congress Presentation
A collaborative working project in primary care: optimising lipid lowering therapies for secondary prevention in high risk patients
4 April 2025
thumbnail
Congress Presentation
The current LDL-C target <1.4mmol/l of the ESC is achieved in less than 16% of patients with Coronary Heart Disease despite effective lipid-lowering therapy: Data from the LLT-R registry
28 August 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources